Precision BioSciences, Inc. announced on January 29, 2025, enhancements within its senior leadership team to drive multiple in vivo gene editing programs. Cindy Atwell was promoted to Chief Development and Business Officer, overseeing all development functions, business development, and alliance oversight.
Cassie Gorsuch, PhD, was promoted to Chief Scientific Officer, responsible for non-clinical development and gene therapy discovery, including preclinical proof of concept and IND-enabling data. These promotions aim to bolster the company's capabilities as it progresses its lead PBGENE-HBV program through Phase 1 clinical study and prepares to advance additional in vivo programs.
The company also announced the retirement of Sam Wadsworth, PhD, from his Director role at Precision BioSciences. These leadership changes are intended to support the company's strategic pivot to an in vivo gene editing focus and accelerate clinical milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.